{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:39:33Z","timestamp":1787697573912,"version":"build-2784847793"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H26 \u2013 ITAKU (MEN) \u2013 IPPAN \u2013 002"],"award-info":[{"award-number":["H26 \u2013 ITAKU (MEN) \u2013 IPPAN \u2013 002"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jaci.2015.09.034","type":"journal-article","created":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T11:01:53Z","timestamp":1447239713000},"page":"1585-1587.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Omalizumab reduces cysteinyl leukotriene and\u00a09\u03b1,11\u03b2-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease"],"prefix":"10.1016","volume":"137","author":[{"given":"Hiroaki","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma","family":"Fukutomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Watai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Sekiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tsuburai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2015.09.034_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/0091-6749(94)90123-6","article-title":"Direct\u00a0evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma","volume":"94","author":"Fischer","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.09.034_bib2","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1164\/ajrccm\/143.5_Pt_1.1025","article-title":"Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects","volume":"143","author":"Christie","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jaci.2015.09.034_bib3","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jaci.2006.07.024","article-title":"Clinical and pathologic perspectives on aspirin sensitivity and asthma","volume":"118","author":"Stevenson","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.09.034_bib4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.09.034_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1939-4551-7-17","article-title":"New strategies with anti-IgE in allergic diseases","volume":"7","author":"Holgate","year":"2014","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2015.09.034_bib6","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.09.034_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2014.07.031","article-title":"A dominant mediator of aspirin-exacerbated respiratory disease","volume":"135","author":"Cahill","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.09.034_bib8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1164\/ajrccm.153.1.8542168","article-title":"Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects","volume":"153","author":"Nasser","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2015.09.034_bib9","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jaci.2009.12.977","article-title":"Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers","volume":"125","author":"Higashi","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.09.034_bib10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.09.034_bib11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaci.2003.10.068","article-title":"Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): involvement of chronic hyperplastic rhinosinusitis with nasal polyposis","volume":"113","author":"Higashi","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.09.034_bib12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaci.2014.04.036","article-title":"The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria","volume":"135","author":"Chang","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.09.034_bibE1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2015.09.034_bibE2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2015.09.034_bibE3","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.rmed.2013.04.017","article-title":"The experience registry: the \u2018real-world\u2019 effectiveness of omalizumab in allergic asthma","volume":"107","author":"Braunstahl","year":"2013","journal-title":"Respir Med"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674915014256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674915014256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:57:48Z","timestamp":1758790668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674915014256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0091674915014256"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2015.09.034","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab reduces cysteinyl leukotriene and\u00a09\u03b1,11\u03b2-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2015.09.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}